Clinical features of gastrointestinal follicular lymphoma

Comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma

Akira Tari, Hideki Asaoku, Masaki Kunihiro, Shinji Tanaka, Megumu Fujihara, Tadashi Yoshino

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We retrospectively compared the clinicopathological features of primary intestinal follicular lymphomas (FL-GIs), nodal follicular lymphomas (FL-LNs) and gastrointestinal MALT lymphomas (MALT-GIs), and investigated the distribution and the endoscopic appearances of FL-GI to evaluate the effectiveness of treatment modality. The subjects were 28 FL-GI patients, 135 FL-LN patients and 70 MALT-GI patients. In FL-LNs the clinical stage III-IV was 83%, while in FL-GIs clinical stage I-II was 68%. In MALT-GIs clinical stage I-II was 87%. The overall survival was significantly better in MALT-GI patients than in FL-LN patients. All FL-GI patients were alive at the time of evaluation. Regarding the histological grade (WHO), grade 1 was 81% in FL-GI, whereas in FL-LN grade 2 was 28% and grade 3 was 11%. The Follicular Lymphoma International Prognostic Index was low in 61% of FL-GIs, while in FL-LNs it was equally distributed to low, intermediate and high, suggesting that the prognosis is better in FL-GIs than in FL-LNs. The clinicopathological studies revealed the FL-GI has intermediate characteristics between FL-LN and MALT-GI. We recommend a 'watch-and-wait' policy or chemotherapy with rituximab for the therapy of FL-GIs because the lesions are often located in broader areas from the lower duodenum to the small intestine.

Original languageEnglish
Pages (from-to)191-197
Number of pages7
JournalDigestion
Volume83
Issue number3
DOIs
Publication statusPublished - Jan 2011
Externally publishedYes

Fingerprint

Marginal Zone B-Cell Lymphoma
Follicular Lymphoma
Duodenum
Small Intestine
Drug Therapy
Survival

Keywords

  • Follicular lymphoma
  • Gastrointestinal follicular lymphoma
  • Gastrointestinal MALT lymphoma
  • Mucosa-associated lymphoid tissue
  • Nodal follicular lymphoma

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Clinical features of gastrointestinal follicular lymphoma : Comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma. / Tari, Akira; Asaoku, Hideki; Kunihiro, Masaki; Tanaka, Shinji; Fujihara, Megumu; Yoshino, Tadashi.

In: Digestion, Vol. 83, No. 3, 01.2011, p. 191-197.

Research output: Contribution to journalArticle

Tari, Akira ; Asaoku, Hideki ; Kunihiro, Masaki ; Tanaka, Shinji ; Fujihara, Megumu ; Yoshino, Tadashi. / Clinical features of gastrointestinal follicular lymphoma : Comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma. In: Digestion. 2011 ; Vol. 83, No. 3. pp. 191-197.
@article{9d8a6d13412d4a6e97ff8727c809ada4,
title = "Clinical features of gastrointestinal follicular lymphoma: Comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma",
abstract = "We retrospectively compared the clinicopathological features of primary intestinal follicular lymphomas (FL-GIs), nodal follicular lymphomas (FL-LNs) and gastrointestinal MALT lymphomas (MALT-GIs), and investigated the distribution and the endoscopic appearances of FL-GI to evaluate the effectiveness of treatment modality. The subjects were 28 FL-GI patients, 135 FL-LN patients and 70 MALT-GI patients. In FL-LNs the clinical stage III-IV was 83{\%}, while in FL-GIs clinical stage I-II was 68{\%}. In MALT-GIs clinical stage I-II was 87{\%}. The overall survival was significantly better in MALT-GI patients than in FL-LN patients. All FL-GI patients were alive at the time of evaluation. Regarding the histological grade (WHO), grade 1 was 81{\%} in FL-GI, whereas in FL-LN grade 2 was 28{\%} and grade 3 was 11{\%}. The Follicular Lymphoma International Prognostic Index was low in 61{\%} of FL-GIs, while in FL-LNs it was equally distributed to low, intermediate and high, suggesting that the prognosis is better in FL-GIs than in FL-LNs. The clinicopathological studies revealed the FL-GI has intermediate characteristics between FL-LN and MALT-GI. We recommend a 'watch-and-wait' policy or chemotherapy with rituximab for the therapy of FL-GIs because the lesions are often located in broader areas from the lower duodenum to the small intestine.",
keywords = "Follicular lymphoma, Gastrointestinal follicular lymphoma, Gastrointestinal MALT lymphoma, Mucosa-associated lymphoid tissue, Nodal follicular lymphoma",
author = "Akira Tari and Hideki Asaoku and Masaki Kunihiro and Shinji Tanaka and Megumu Fujihara and Tadashi Yoshino",
year = "2011",
month = "1",
doi = "10.1159/000321814",
language = "English",
volume = "83",
pages = "191--197",
journal = "Digestion",
issn = "0012-2823",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Clinical features of gastrointestinal follicular lymphoma

T2 - Comparison with nodal follicular lymphoma and gastrointestinal MALT lymphoma

AU - Tari, Akira

AU - Asaoku, Hideki

AU - Kunihiro, Masaki

AU - Tanaka, Shinji

AU - Fujihara, Megumu

AU - Yoshino, Tadashi

PY - 2011/1

Y1 - 2011/1

N2 - We retrospectively compared the clinicopathological features of primary intestinal follicular lymphomas (FL-GIs), nodal follicular lymphomas (FL-LNs) and gastrointestinal MALT lymphomas (MALT-GIs), and investigated the distribution and the endoscopic appearances of FL-GI to evaluate the effectiveness of treatment modality. The subjects were 28 FL-GI patients, 135 FL-LN patients and 70 MALT-GI patients. In FL-LNs the clinical stage III-IV was 83%, while in FL-GIs clinical stage I-II was 68%. In MALT-GIs clinical stage I-II was 87%. The overall survival was significantly better in MALT-GI patients than in FL-LN patients. All FL-GI patients were alive at the time of evaluation. Regarding the histological grade (WHO), grade 1 was 81% in FL-GI, whereas in FL-LN grade 2 was 28% and grade 3 was 11%. The Follicular Lymphoma International Prognostic Index was low in 61% of FL-GIs, while in FL-LNs it was equally distributed to low, intermediate and high, suggesting that the prognosis is better in FL-GIs than in FL-LNs. The clinicopathological studies revealed the FL-GI has intermediate characteristics between FL-LN and MALT-GI. We recommend a 'watch-and-wait' policy or chemotherapy with rituximab for the therapy of FL-GIs because the lesions are often located in broader areas from the lower duodenum to the small intestine.

AB - We retrospectively compared the clinicopathological features of primary intestinal follicular lymphomas (FL-GIs), nodal follicular lymphomas (FL-LNs) and gastrointestinal MALT lymphomas (MALT-GIs), and investigated the distribution and the endoscopic appearances of FL-GI to evaluate the effectiveness of treatment modality. The subjects were 28 FL-GI patients, 135 FL-LN patients and 70 MALT-GI patients. In FL-LNs the clinical stage III-IV was 83%, while in FL-GIs clinical stage I-II was 68%. In MALT-GIs clinical stage I-II was 87%. The overall survival was significantly better in MALT-GI patients than in FL-LN patients. All FL-GI patients were alive at the time of evaluation. Regarding the histological grade (WHO), grade 1 was 81% in FL-GI, whereas in FL-LN grade 2 was 28% and grade 3 was 11%. The Follicular Lymphoma International Prognostic Index was low in 61% of FL-GIs, while in FL-LNs it was equally distributed to low, intermediate and high, suggesting that the prognosis is better in FL-GIs than in FL-LNs. The clinicopathological studies revealed the FL-GI has intermediate characteristics between FL-LN and MALT-GI. We recommend a 'watch-and-wait' policy or chemotherapy with rituximab for the therapy of FL-GIs because the lesions are often located in broader areas from the lower duodenum to the small intestine.

KW - Follicular lymphoma

KW - Gastrointestinal follicular lymphoma

KW - Gastrointestinal MALT lymphoma

KW - Mucosa-associated lymphoid tissue

KW - Nodal follicular lymphoma

UR - http://www.scopus.com/inward/record.url?scp=79251585243&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79251585243&partnerID=8YFLogxK

U2 - 10.1159/000321814

DO - 10.1159/000321814

M3 - Article

VL - 83

SP - 191

EP - 197

JO - Digestion

JF - Digestion

SN - 0012-2823

IS - 3

ER -